Skip to main content
Atrás
DNTH logo

Dianthus Therapeutics, Inc.

Calidad de datos: 100%
DNTH
NASDAQ Healthcare Biotechnology
$78.55
▼ $0.77 (-0.97%)
Cap. Mercado: 2.84B
Rango del Día
$76.42 $80.28
Rango de 52 Semanas
$13.37 $88.02
Volumen
852,060
Promedio 50D / 200D
$56.34 / $37.05
Cierre Anterior
$79.32

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -17.5 0.3
P/B 5.8 2.9
ROE % -38.4 3.7
Net Margin % -7973.3 3.8
Rev Growth 5Y % 8.4 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$101.00 +28.6%
Low: $55.00 High: $145.00
EPS Futuro
-$4.30
Ingresos Est.
1.5 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $2.60
-$0.25 – $10.68
670 M 4
FY2029 -$3.70
-$15.21 – $0.36
200 M 4
FY2028 -$5.47
-$8.72 – -$3.31
19 M 11

Puntos Clave

Revenue grew 8.37% annually over 5 years — modest growth
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -129.27M
Revenue growth is decelerating — 1Y growth trails 5Y average by 75.72%

Crecimiento

Revenue Growth (5Y)
8.37%
Revenue (1Y)-67.35%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-38.38%
ROIC-26.97%
Net Margin-7973.33%
Op. Margin-8739.34%

Seguridad

Debt / Equity
0.00
Current Ratio13.32
Interest Coverage0.00

Valoración

P/E Ratio
-17.52
P/B Ratio5.76
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -67.35% Revenue Growth (3Y) -15.12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8.37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.04M Net Income (TTM) -162.34M
ROE -38.38% ROA -30.58%
Gross Margin 100.00% Operating Margin -8739.34%
Net Margin -7973.33% Free Cash Flow (TTM) -129.27M
ROIC -26.97% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 13.32
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -17.52 P/B Ratio 5.76
P/S Ratio 1397.07 PEG Ratio -0.15
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.84B Enterprise Value 2.79B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.04M 6.24M 2.83M 6.42M 1.48M
Net Income -162.34M -84.97M -43.56M -28.48M -13.11M
EPS (Diluted) -4.20 -2.55 -8.45 -7.60 -3.82
Gross Profit 2.04M 6.24M 2.83M 6.42M 1.48M
Operating Income -177.93M -101.86M -48.17M -29.71M -13.09M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 530.92M 374.01M 179.41M 83.11M 189.93M
Total Liabilities 37.52M 21.53M 10.54M 9.45M 17.26M
Shareholders' Equity 493.40M 352.48M 168.87M 73.66M 172.67M
Total Debt 1.39M 1.49M 585,000.0 788,000.0 0.0
Cash & Equivalents 51.09M 22.79M 132.33M 15.37M 131.65M
Current Assets 409.44M 280.90M 177.45M 82.03M 180.69M
Current Liabilities 30.73M 18.45M 9.63M 8.23M 10.86M